Funder: National Institutes of Health

Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision) | October 16, 2026 (New) | November 16, 2026 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; project period max 2 years.

Summary: Supports exploratory studies on the mechanisms by which incretin mimetics (GLP-1, GIP-1, or dual agents) impact cancer risk, focusing on preclinical and patient-based research rather than short-term outcomes.

Key Information: Clinical trials are not allowed; mechanistic studies must use samples from animals or humans exposed to incretin mimetics and include cancer endpoints or biomarkers.